The Same Cancer, Two Different Drugs: What Tumor Genomic Testing (NGS, MSI, PD-L1) Decides
Two people get the same diagnosis. Same organ, same cell type, same words on the chart. Then one is put on a pill that targets a single mutation, and the other is put on an immunotherapy infusion. Same cancer, different drug. That gap is not a mistake. It is the point. The organ names the cancer, but the biology inside the tumor increasingly names the treatment, and that biology only shows up if someone tests for it. Turning a genomic profile into the right drug is a matching problem, and matching your tumor's biology to the evidence is exactly what Healz is built to do.
This is not new medicine dressed up. It is a real shift in how cancer is treated, and it turns on one question that is easy to skip: was your tumor actually profiled, and did anyone read the result against what the drugs require?
The same diagnosis, two different drugs
For a long time, the organ decided almost everything. Lung cancer got lung cancer treatment. Colon cancer got colon cancer treatment. The name on the biopsy set the plan.
That still holds for the basics, but the ceiling has moved. The NCI states that some targeted therapies and immunotherapies only work for cancers carrying a specific biomarker. So two tumors that look identical under the microscope can respond to completely different drugs, because the thing being matched is not the organ. It is the molecular alteration driving the cancer. Miss the alteration, and you are aiming a general treatment at a cancer that had a specific weak point nobody looked for.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Actionable targets, where one alteration opens one drug
Some alterations act like a keyhole. Find the exact one, and a drug built for it becomes available.
Next-generation sequencing reads many genes at once from the tumor tissue and reports which alterations are present. The NCCN lung cancer panel recommends broad molecular profiling that covers, at minimum, alterations in genes like EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK, because each can change the first-line treatment. EGFR, ALK, ROS1, BRAF, and NTRK-positive cancers all have FDA-approved targeted drugs.
A few examples make the logic concrete. BRAF V600E is the most common BRAF alteration and has its own targeted regimen. KRAS G12C, long considered undruggable, now has a selective inhibitor. NTRK gene fusions are treated with drugs the FDA approved regardless of where the tumor started, which is why a biomarker can matter more than the organ. The catch is simple: a targeted drug only helps if the target is actually there, and the only way to know is to test.
The immunotherapy biomarkers answer a different question
Targeted therapy asks "is there a specific alteration to attack?" Immunotherapy asks a different question: "will this tumor respond to having the immune system unleashed on it?" Different biomarkers answer it.
Microsatellite instability-high (MSI-high), also called mismatch-repair-deficient (dMMR), is an established predictor of response to immune checkpoint blockade. These tumors carry a heavy mutation load that makes them visible to the immune system, and pembrolizumab was approved for MSI-high or dMMR tumors across multiple cancer types regardless of origin. High tumor mutational burden (TMB) points the same way, and the NCI lists TMB among the biomarkers used to determine immunotherapy eligibility. PD-L1, a protein measured on tumor cells, helps guide some immunotherapy decisions in cancers like non-small cell lung cancer. So a tumor with no targetable mutation is not out of options. It may still carry an immunotherapy signal, but only if MSI, TMB, and PD-L1 were part of the workup.
"No target" is information, and germline is not somatic
Two honest limits keep this from being magic. First, not every tumor has an actionable finding. The NCI is direct that sometimes the test finds no biomarker matching an available therapy. That is not a failed test. It is a real result that closes off guesswork and keeps the plan on solid ground instead of a hoped-for target.
Second, tumor testing and inherited testing are not the same thing. Somatic testing (also called tumor testing) looks at acquired alterations in the tumor itself and is used to pick treatment. Germline testing uses blood or saliva to look for inherited mutations present in every cell since birth, and it answers a different question: family risk, not this drug. The NCI notes biomarker testing is different from genetic testing for inherited risk. Reading a somatic result as if it were germline, or the reverse, sends the whole conversation the wrong way.
How Healz matches your tumor's biology to the evidence
Here the matching stops being guesswork. With Healz, everything sits in one place, one chat instead of ten apps. Frontier AI reads your tumor genomic report as one connected case rather than a page of gene names and percentages.
Its root-cause technology does the real work. It takes the NGS, MSI, PD-L1, and TMB results and lines them up against what the drugs actually require. It drills past the organ the cancer started in to the specific alteration driving it. It cross-checks your profile against more than a million cases, so the match is to your biology, not a generic label.
Memory holds your report and your history in the same chat, working with the root-cause technology so nothing you upload gets lost. Used as an AI oncologist and a second opinion on your own profile, it does three things by design. It checks whether the actionable targets were tested at all, so an EGFR or ALK or NTRK result that was never run does not quietly disappear. It reads the immunotherapy biomarkers together, so an MSI-high, high-TMB, or PD-L1 finding is not missed while everyone waits on a targeted therapy match. And it keeps the somatic tumor result separate from any germline question, so the profile is used for the decision it can actually answer.
When you want expert eyes on it, you can bring a board-certified doctor into the same chat for a second opinion.
Five ways to get the most from tumor genomic testing
- Ask whether NGS was done, not just a single-gene test. Broad profiling reads many genes at once. A test that checked one alteration and stopped can miss the very target that changes the plan.
- Separate the targeted question from the immunotherapy question. One asks if there is a specific alteration to attack. The other asks about MSI, TMB, and PD-L1. A tumor can strike out on one and win on the other.
- Chase "no result" for the biomarkers that matter. If MSI-high status or PD-L1 was never reported, the immunotherapy path was never fully checked. Read the genomic page the same careful way you would read the rest of the pathology report.
- Know if your result is somatic or germline. Tumor testing picks your treatment. Inherited testing speaks to family risk. Confusing them answers the wrong question.
- Bring the profile into a full treatment-plan review. A single alteration can reshape the whole approach, which is exactly why a genomic result belongs inside a real second-opinion on the treatment plan, not read in isolation.
The same cancer really can need two different drugs. Which one is yours is written in the tumor's biology, and that answer only arrives if someone tests for it and reads the result against the evidence.
Healz was built to match your tumor's biology to the drug the evidence points to. The wise run Healz.
Frequently asked questions
- What is tumor genomic testing, and how is it different from genetic testing?
Tumor genomic testing, also called biomarker or somatic testing, looks at the alterations inside a tumor to help pick treatment, per the NCI. It often uses next-generation sequencing to read many genes at once. It is different from inherited genetic testing, which uses blood or saliva to look for mutations present in every cell since birth and speaks to family cancer risk, not to which drug will work on this tumor.
- What are actionable mutations in cancer?
Actionable mutations are alterations that a specific drug is built to attack. Common examples include EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, and NTRK fusions, each tied to an FDA-approved targeted therapy (NCCN, NCI). Some, like NTRK fusion drugs, are approved regardless of where the cancer started, which is why the alteration can matter more than the organ. A targeted drug only helps if the target is actually present, so testing comes first.
- What do MSI-high and PD-L1 mean for cancer treatment?
They point toward immunotherapy rather than targeted therapy. MSI-high, or mismatch-repair-deficient, tumors respond well to immune checkpoint drugs like pembrolizumab, which was approved for these tumors across many cancer types. High tumor mutational burden (TMB) points the same way, and PD-L1 expression helps guide some immunotherapy decisions. A tumor with no targetable mutation may still carry one of these immunotherapy signals.
- Does every cancer have a genomic target for treatment?
No. The NCI is clear that sometimes biomarker testing finds no marker that matches an available therapy. That is a real result, not a failed test, and it keeps the treatment plan grounded in what is proven rather than a hoped-for target. Testing is most often recommended for advanced cancer and is routine in cancers like non-small cell lung, breast, and colorectal.
Written by Healz Team · Filed under Health Insights